Standigm signs MoU with Merck Korea for AI drug discovery research
Under the MOU, Standigm will accelerate its drug discovery research by adopting Merck’s SYNTHIA™ artificial intelligence software. which can help the new synthesis of Standigm compounds. SYNTHIA™ is a computer-aided retrosynthetic design tool and combines network theory, modern high-powered computing, and expert chemical knowledge to rapidly design synthetic pathways.
“Applying AI to the drug discovery process can significantly reduce the time needed to discover new drug candidates and find optimized synthetic routes,” said Sojeong Yun, co-founder and CEO of Standard. “By pooling know-how in AI synthesis from Merck’s AI technology and Standigm, we expect better results in drug discovery faster, compared to the traditional drug discovery method. drugs by AI,” she added.
“The discovery of candidate chemicals using AI technology for the development of new drugs plays a crucial role in the growth of the local bio-industry,” said Stephen Nam-Koo Leeresponsible for scientific and laboratory solutions for South KoreaLife Sciences business area, Merck Korea.
As a leading company in the field of AI drug discovery, Standigm has been actively researching AI technology in organic synthesis in its own Synthetic Research Center, established last year.
Standigm is an AI-based drug discovery company headquartered in Seoul, South Korea and Standigm has expanded its operations around the world, recently opening offices in the US and UK. Standigm has proprietary AI platforms spanning novel target identification through compound design to generate commercially valuable drug pipelines. Founded in 2015, Standigm has implemented an early-stage drug discovery workflow AI to generate multiple First-in-Class compounds in seven months. Pursuing the comprehensive industrialization of AI-driven drug discovery, Standigm has realized the automation of the molecular design workflow, and the automation effort has extended to the entire drug discovery process. drugs based on Standigm’s AI platforms, including Standigm ASK™ for novel target discovery, Standigm BEST™ for novel compound generation. Learn more about http://www.standigm.com.
Merck(NYSE: MRK), a leading science and technology company, operates in life sciences, healthcare and electronics. Approximately 60,000 employees work every day to make a positive difference in the lives of millions of people by creating more joyful and sustainable lifestyles. From advancing gene-editing technologies, to discovering unique ways to treat the toughest diseases, to enabling device intelligence, the company is everywhere. In 2021, Merck achieved a turnover of 19.7 billion euros in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advancements. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly traded company. Merck owns the worldwide rights to the Merck name and brand. The only exceptions are United States and Canadawhere Merck’s business segments operate as MilliporeSigma in life sciences, EMD Serono in healthcare, and EMD Electronics in electronics.